Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20937296 | 0.83 | ITK (0.44) | ALDH1A1MTNR1AMTNR1BNQO2HRH4 | |
| SCHEMBL31501965 | 0.81 | CYP2A6 (0.37) | ALDH1A1CYP2A6NQO2ERN1KDM4E | |
| SCHEMBL26660799 | 0.81 | CYP2A6 (0.37) | ALDH1A1CYP2A6NQO2ERN1KDM4E | |
| SCHEMBL29955346 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MTNR1AMTNR1BNQO2HRH4 | |
| SCHEMBL28059088 | 0.79 | CYP19A1 (0.48) | ALDH1A1CYP2A6NQO2ERN1PDE3B | |
| SCHEMBL2668598 | 0.78 | SLC40A1 (0.55) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL5366835 | 0.77 | DAO (0.53) | ALDH1A1CYP2A6HRH4DAOKDM4E | |
| SCHEMBL13360133 | 0.77 | LMNA (0.40) | ALDH1A1CYP2A6MAPTKMT2ALMNA | |
| SCHEMBL31501813 | 0.76 | MAPT (0.51) | CYP2A6ERN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL26660827 | 0.76 | MAPT (0.51) | CYP2A6ERN1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| CN-119855589-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-111225915-B | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | Jubilant Epipad LLC (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3697785-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-07-30 | — | — | US | disclosed |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-07-30 | — | — | US | disclosed |
| CN-111225915-A | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019077631-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019077631-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI1, PADI6 | ALDH1A1 163/4885CYP2A6 1160/4885MTNR1A 4495/4885 |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | PADI4, PADI1, PADI2 | ALDH1A1 402/4885CYP2A6 719/4885MTNR1A 4492/4885 |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | PADI4, PADI1, PADI2 | ALDH1A1 402/4885CYP2A6 719/4885MTNR1A 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.